secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACHIEVE LIFE SCIENCES, INC. (ACHV)
CIK:        0000949858
Form:       8-K
Filed at:   2026-08-14T20:09:26+00:00
Accession:  0001193125-26-352229
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01, 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Achieve Life Sciences enters $150M ATM offering with Jefferies for cytisinicline funding
--------------------------------------------------------------------------------

- Entered Open Market Sale Agreement with Jefferies LLC for up to $150M in common stock ATM sales.
- Jefferies receives up to 3.0% commission on gross proceeds; company may suspend or terminate at any time.
- Proceeds to fund commercialization of cytisinicline and Phase 3 trial for e-cigarette cessation.
- Shares sold under existing Form S-3 registration statement filed Jan 23, 2026; no obligation to sell.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/949858/000119312526352229/0001193125-26-352229-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/949858/000119312526352229/achv-20260814.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-352229

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer